Healthcare & Life Sciences Insights

Discover Latham’s latest insights into the commercial, regulatory, and legal developments shaping the global healthcare and life sciences landscape.

Latham’s cross-disciplinary team delivers insightful, practical guidance and sophisticated representation to a full spectrum of healthcare and life sciences companies across the globe, on every type of transaction or dispute a company may face.

Learn more about our capabilities

Pipetting a DNA (deoxyribonucleic acid) sample into a multiwell plate with DNA information in the background

In the Spotlight

Healthcare & Life Sciences Market Update

Shiny transparent capsule filled with colorful spheres

June 2, 2025 Newsletter

Healthcare & Life Sciences: Drug Pricing Digest — Number 47

Close-up of pipette releasing clear liquid droplet into a petri dish with DNA sequencing image in background.

May 16, 2025 Blog

100 Days In: FDA Updates and Trends to Watch

artificial intelligence machine learning big data concept

April 17, 2025 Blog

Preparing for the European Health Data Space — Opportunities and Challenges for Europe’s Digital Future

March 5, 2025 Blog

HHS Issues Policy Statement to Expand Use of Rulemaking Without Notice and Comment

Multi-color tablet and capsule pills lying on a white surface.

July 8, 2025 Client Alert

Senators Introduce Legislation to Restrict Direct-to-Consumer Drug Advertising

The End Prescription Drug Ads Now Act would prohibit direct-to-consumer advertising and promotion of prescription drugs and biologics.

LIF_Reeves-1600x1080-THUMB-LightBlue_V01

July 7, 2025 Video

Latham in Focus: Healthcare & Life Sciences Competition Considerations

What antitrust issues do healthcare and life sciences companies need to consider as they plan their next deal?

June 30, 2025 Newsletter

Healthcare & Life Sciences: Drug Pricing Digest — Number 49

June 26, 2025 Webcast

Access Denied — Navigating the New DOJ Data Security Program With Confidence

June 24, 2025 Podcast

Episode 99 — Drug Pricing: Takeaways From the Philadelphia Pricing and Contracting USA Conference

Digitally rendered gel capsule filled with multicolor spheres.

June 24, 2025

Episode 99 — Drug Pricing: Takeaways From the Philadelphia Pricing and Contracting USA Conference

Join the Latham team and Allan Thoen from Sandoz to hear about the key themes and highlights from one of the year’s significant drug pricing conferences.

Abstract background of wires and glowing particles

June 26, 2025

Access Denied — Navigating the New DOJ Data Security Program With Confidence

Latham’s team of lawyers focusing on data security and national security examine DOJ’s DSP and its potential implications for companies. MCLE credit offered.

June 06, 2025

Episode 98 — Drug Pricing: Takeaways From the MDMA Annual Meeting

One of the country’s largest medical innovation and policy conferences recently concluded in Washington, D.C. Join the Latham team to discuss takeaways from the meeting, including regulatory changes and compliance hot topics.

May 02, 2025

Episode 97 — Drug Pricing: How the Drug Pricing EO Impacts FDA and Overlaps With Grassley-Led Legislation

On April 15, President Trump signed an executive order addressing prescription drug prices. The Latham team analyzes how the EO might impact FDA and dovetails with five bills recently (re-)introduced in the Senate.

March 12, 2025

Episode 95 — Drug Pricing: FDA in the Age of Executive Orders and DOGE

The Department of Government Efficiency, Trump executive orders, and a recent Office of Management and Budget memorandum are making drastic changes at FDA. The Latham team discusses the potential impacts on FDA approval and enforcement activities, including with respect to novel tobacco and nicotine products.

February 25, 2025

Episode 94 — Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook

One of the country’s largest healthcare conferences recently concluded in San Francisco. Join the Latham team to discuss takeaways from the conference, including AI innovation and increased dealmaking activity, and consider the policy outlook under the new Trump administration.

Drop of clear blue liquid from droper droping to test tube in laboratory with bright color blur background.

December 30, 2024

Episode 89 — The Growth Rocketship: How BridgeBio’s Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech — Then, Now, and What’s Next?

Latham speaks with BridgeBio’s CEO/founder and CFO about BBIO’s growth story — its past, present, and future.

December 17, 2024

Episode 88 — Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities?

Explore recent FDA enforcement trends and the agency’s current focus, and consider potential priorities under the incoming Trump Administration.

November 26, 2024

Episode 87 — Drug Pricing: What’s in the New CMS Medicaid Final Rule?

CMS sought far-reaching changes to the Medicaid Drug Rebate Program in its 2023 proposed rule implementing the Medicaid Services Investment and Accountability Act. Find out which proposals CMS dropped from the final rule, and which changes became effective November 19, 2024.

October 21, 2024

Episode 86 — Drug Pricing: Takeaways From the Chicago Medicaid Drug Rebate Program Summit

One of the year’s major drug pricing conferences just concluded in Chicago. Join the Latham team to discuss takeaways from the conference, including highlights from remarks by government speakers.

Front View of US Supreme Court in Washington DC, including the inscription Equal Justine Under Law

September 19, 2024

The Demise of Chevron Deference and Its Impact on the Healthcare and Life Sciences Industries

Latham lawyers discuss the implications of the US Supreme Court decision in Loper Bright. MCLE credit offered.

September 19, 2024

Episode 85 — Drug Pricing: How the Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry

Recent Supreme Court decisions, such as those overruling Chevron deference, as well as ongoing manufacturer challenges to the Inflation Reduction Act and state 340B laws, will likely have a significant impact on the pharmaceutical industry.

August 19, 2024

Episode 83 — Drug Pricing: How Are Payers Responding to the IRA?

Explore how health insurance companies are adapting to the Inflation Reduction Act's new requirements, including the Part D redesign.

June 21, 2024

Episode 82 — Drug Pricing: Takeaways From the New Orleans Pricing and Contracting USA Conference

One of the year’s major drug pricing conferences just concluded in New Orleans. Join the Latham team to discuss takeaways from the conference, with topics including 340B developments, state legislative activity, and IRA implementation.

June 13, 2024

Episode 81 — Drug Pricing: A Look Behind the Curtain of the New ASP Reporting Website and Other Data Collection Portals

The new ASP reporting website highlights the increasing significance of data collection portals — and yet the number of permitted users is very small. Join us as we learn from leading practitioners at Riparian how to navigate the complex web of compliance requirements.

Our Archive

Close-up of syringe with needle resting on vial filled with liquid.

July 8, 2025 In the News

Judge Tosses Teva Suit Over Generic Drug Patent Deal

An Indiana federal judge has thrown out a lawsuit brought by generic-drug maker Teva Pharmaceuticals USA Inc. alleging Eli Lilly and Co. breached a settlement agreement over the osteoporosis drug Forteo.

A glass dropper or pipette releases a clear liquid into a test tube.

July 8, 2025 Our Work

Latham Advises Cargo Therapeutics in Acquisition by Concentra Biosciences for US$4.379 in Cash Per Share Plus a Contingent Value Right via a Tender Offer

Multidisciplinary team represents the biotechnology company in the transaction.

July 3, 2025 Our Work

Latham Advises on Portal Biotech’s US$35 Million Series A

July 2, 2025 Our Work

Latham & Watkins Advises on Scientia Vascular’s US$30 Million Growth Facility

July 2, 2025 Our Work

Latham Represents Neuberger Berman Capital Solutions in Completed Strategic Investment in Paradigm

Soft focus bokeh light effects over a rippled, blue water background in the pool.

June 23, 2025 Recognition

Latham Recognized With Six LMG Life Sciences EMEA Awards 2025

The firm and three lawyers were honored with major awards, including Deal of the Year and Lawyer of the Year.

Badges and Logos_Legal 500 Top Tier Firm_2025_900x450.png

June 11, 2025 Recognition

Latham Outpaces All Firms in Legal 500 US Guide

Latham earns more Tier 1 rankings than any other firm.

Abstract blue light and shade triangle shape creative background illustration.

May 23, 2025 Recognition

Seven Latham Partners Chosen to GCR’s Top Women in Antitrust

Global Competition Review’s list honors the world’s leading antitrust practitioners, recognizing their influential contributions and achievements in the field.

Capital Markets European Union Life Sciences Regulatory FDA Regulatory Healthcare & Life Sciences Healthcare Regulatory Intellectual Property Litigation Life Sciences Licensing Litigation & Trial Mergers & Acquisitions Private Equity Public Company Representation Securities and M&A Litigation Technology

The Book of Jargon® Series

Book of Jargon Healthcare & Life Sciences

Download the App

Endogenous

The Book of Jargon® – Healthcare & Life Sciences

produced within, or originating from within, the body or one of its parts.

Word of the Day®

Excipient

The Book of Jargon® – Healthcare & Life Sciences

an inactive ingredient intentionally added to a therapeutic or diagnostic product that is not intended to exert a therapeutic effect (though it may improve product delivery, such as by enhancing absorption or controlling Drug substance release). According to the FDA, Excipients may include fillers, extenders, diluents, wetting agents, solvents, emulsifiers, preservatives, flavors, absorption enhancers, sustained-release matrices and coloring agents, but do not include process- or product-related impurities such as degradation products, leachates or residual solvents or extraneous contaminants.

Word of the Day®

Local Coverage Determination (LCD)

The Book of Jargon® – Healthcare & Life Sciences

a Coverage determination by a Medicare Administrative Contractor (MAC) regarding whether a particular service or item is reasonable and necessary under Medicare within such MAC’s geographical jurisdiction. MACs publish LCDs to provide guidance to the public and medical community within the MAC’s jurisdictions on the terms and conditions of Coverage for services and items. Contractors develop LCDs by considering medical literature, the advice of local medical societies and medical consultants, public comments, and comments from the provider community.

Word of the Day®

Management Services Organization (MSO)

The Book of Jargon® – Healthcare & Life Sciences

a for-profit or non-profit corporation, general or limited partnership, or limited liability company providing a variety of services for or on behalf of one or more medical practices (or other healthcare entities such as a hospital). Generally, the services include a broad range of management, financial and administrative services, often the entire administrative requirements or “back office” of a healthcare Provider. In many cases, the MSO acquires the tangible assets of the medical practices and leases them back to the practice as part of a management services fee. The MSO may also perform services such as marketing (where permitted under state law), contract procurement and administration, and purchase of capital assets. MSOs are often established by hospitals or by hospitals in conjunction with physicians, to assist in the consolidation of medical practices and the business development of the resulting group practice. An MSO created by a hospital and physicians is not an integrated organization, as no merger or consolidation directly occurs between the hospital and medical practice.

Word of the Day®

Medicaid

The Book of Jargon® – Healthcare & Life Sciences

a federal health insurance program authorized by Title XIX of the Social Security Act that is jointly funded by the federal and respective state governments, and administered by the state. The program provides health insurance and other services to persons of all ages whose income and resources meet means-tested eligibility criteria determined by each state and approved by CMS. Recipients of Medicaid must be US citizens or permanent residents. The scope of Coverage provided by the various state Medicaid programs must meet certain minimum criteria established in federal law and regulations; however, payment methodologies and other administrative aspects of the Medicaid program are left to the respective state. The ACA significantly expanded both eligibility for and federal funding of Medicaid.

Word of the Day®